Literature DB >> 1833809

Red man syndrome with teicoplanin.

S Dubettier, A Boibieux, M Lagable, L Crevon, D Peyramond, H Milon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1833809     DOI： 10.1093/clinids/13.4.770

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN： 0162-0886


× No keyword cloud information.
  4 in total

Review 1.  Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.

Authors:  C M Spencer; H M Bryson
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

Review 2.  A risk-benefit assessment of teicoplanin in the treatment of infections.

Authors:  F de Lalla; A Tramarin
Journal:  Drug Saf       Date:  1995-11       Impact factor: 5.606

3.  Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin.

Authors:  M J Rybak; E M Bailey; L H Warbasse
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

Review 4.  Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.